179 related articles for article (PubMed ID: 37309025)
1. Current Advances in Graft-versus-host Disease After Intestinal Transplantation.
Oza K; Kang J; Patil D; Owen KL; Cui W; Khan K; Kaufman SS; Kroemer A
Transplantation; 2024 Feb; 108(2):399-408. PubMed ID: 37309025
[TBL] [Abstract][Full Text] [Related]
2. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
4. Current status of graft-versus-host disease after intestinal transplantation.
Ganoza A; Mazariegos GV; Khanna A
Curr Opin Organ Transplant; 2019 Apr; 24(2):199-206. PubMed ID: 30762668
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease: why have we not made more progress?
Jaglowski SM; Devine SM
Curr Opin Hematol; 2014 Mar; 21(2):141-7. PubMed ID: 24468835
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
[TBL] [Abstract][Full Text] [Related]
8. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
9. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
10. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
11. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances in pathophysiology, diagnosis and treatment of steroid-refractory graft-versus-host disease].
Toubai T; Torii Y
Rinsho Ketsueki; 2021; 62(11):1557-1566. PubMed ID: 34866077
[TBL] [Abstract][Full Text] [Related]
13. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in ocular graft-versus-host disease.
Cheng X; Huang R; Huang S; Fan W; Yuan R; Wang X; Zhang X
Front Immunol; 2023; 14():1092108. PubMed ID: 36761771
[TBL] [Abstract][Full Text] [Related]
15. Novel targets in the treatment of chronic graft-versus-host disease.
Im A; Hakim FT; Pavletic SZ
Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
[TBL] [Abstract][Full Text] [Related]
16. NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme.
Zhang P; Yang S; Zou Y; Yan X; Wu H; Zhou M; Sun YC; Zhang Y; Zhu H; Xu K; Wang Y; Sheng LX; Mu Q; Sun L; Ouyang G
BMC Immunol; 2019 Dec; 20(1):46. PubMed ID: 31818250
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of graft-versus-host disease.
Iwasaki T
Clin Med Res; 2004 Nov; 2(4):243-52. PubMed ID: 15931364
[TBL] [Abstract][Full Text] [Related]
18. T-cell chimerism prior to graft-versus-host disease.
Noguchi M; Shindo T; Yamada Y; Date H
Eur J Cardiothorac Surg; 2021 Jul; 60(1):194-196. PubMed ID: 33495782
[TBL] [Abstract][Full Text] [Related]
19. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
20. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
